Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2018-08-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort. In the Combination Dose Finding cohort and the Combination Expansion cohort, we will combine cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer (CRC). In the Monotherapy MET Amplified cohort, we will screen at least 50 patients for MET gene amplification ("MET amplification"). Patients with MET amplification will receive cabozantinib only (monotherapy).

The primary objective of this open-label phase Ib trial are:

1. To determine the maximum tolerated dose and the recommended phase II dose for the combination of cabozantinib and panitumumab in patients with KRAS wild-type metastatic colorectal cancer and
2. To identify the objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer.

The secondary objectives are:

1. To describe the non-dose limiting toxicities of cabozantinib and panitumumab.
2. To describe the clinical activity (ORR, PFS, OS) of cabozantinib and panitumumab.
3. To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer.
4. To describe the clinical activity (PFS, OS) of cabozantinib monotherapy in patients with MET amplified colorectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NCT00788957

Colon Cancer Colorectal Cancer Gastrointestinal Cancer +2 more

COMPLETED PHASE1/PHASE2

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

NCT00891930

Metastatic Colorectal Cancer

COMPLETED PHASE2

Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

NCT00842257

Colorectal Cancer

COMPLETED PHASE2

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

NCT04117945

BRAF V600E Negative KRAS Gene Mutation Negative Locally Advanced Unresectable Colorectal Adenocarcinoma +10 more

ACTIVE_NOT_RECRUITING PHASE2

Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer

NCT01126112

Colorectal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cabozantinib and Panitumumab

60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.

Group Type EXPERIMENTAL

Panitumumab

Intervention Type BIOLOGICAL

The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.

Cabozantinib

Intervention Type DRUG

There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.

Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily.

Cabozantinib

60 mg Cabozantinib PO daily.

Group Type EXPERIMENTAL

Cabozantinib

Intervention Type DRUG

There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.

Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Panitumumab

The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.

Intervention Type BIOLOGICAL

Cabozantinib

There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.

Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vectibix Cometriq

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically and/or cytologically confirmed and radiographically measurable KRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable. Subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment.
2. Prior treatment with anti-EGFR therapy (either panitumumab or cetuximab).
3. At least one site of disease that is measurable by RECIST (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation.
4. Age ≥ 18 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
6. Life expectancy greater than 3 months.
7. Capable of understanding and complying with the protocol requirements and has signed the informed consent document.
8. Adequate organ and marrow function as defined below:

Absolute neutrophil count ≥ 1,000/μl without colony stimulating factor support

Platelets ≥ 75,000/μl

Hemoglobin ≥ 8 g/dL

AST/ALT ≤ 3 X upper limit of normal (ULN)

Total bilirubin ≤ 1.5 X upper limit of normal (ULN)

Serum albumin ≥ 2.5 g/dL

1. For the Monotherapy MET Amplified cohort only: MET gene amplification by prospective screening assay from peripheral blood.
2. Histologically and/or cytologically confirmed and radiographically measurable KRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable. Subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment. In addition, for the monotherapy MET Amplified cohort, must have received prior treatment with anti-EGFR therapy (either panitumumab or cetuximab).
3. At least one site of disease that is measurable by RECIST (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation.
4. Age ≥ 18 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. Life expectancy greater than 3 months.
7. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s).
8. Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose of study treatment.
9. Capable of understanding and complying with the protocol requirements and has signed the informed consent document.
10. Adequate organ and marrow function as defined by protocol.

Exclusion Criteria

1. Presence of or known history of brain/ CNS tumor or metastases.
2. KRAS exon 2 (codons 12 or 13) mutation detected in tumor tissue specimen.
3. Concurrent severe and/or uncontrolled medical conditions which may compromise participation in the study, including impaired heart function or clinically significant heart disease.
4. Concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel). Low dose aspirin (≤ 81 mg/day), low-dose warfarin (≤ 1 mg/day), and prophylactic LMWH are permitted.
5. Previously experienced any of the following:

1. clinically significant gastrointestinal bleeding within the last 6 months
2. hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within the last 3 months
3. any other signs indicative of pulmonary hemorrhage within the last 3 months
6. Radiographic evidence of cavitating pulmonary lesion(s).
7. Tumor in contact with, invading or encasing any major blood vessels.
8. Evidence of endotracheal or endobronchial tumor.
9. Uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

1. Cardiovascular disorders including:

i. Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening

ii. Any history of congenital long QT syndrome

iii. Any of the following within the last 6 months:

1. unstable angina pectoris
2. clinically-significant cardiac arrhythmias
3. stroke (including TIA, or other ischemic event)
4. myocardial infarction
5. thromboembolic event requiring therapeutic anticoagulation Note: Subjects with a venous filter (e.g., vena cava filter) are not eligible for this study.

b. Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: i. Any of the following within the last 28 days:



1. active peptic ulcer disease
2. active inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
3. malabsorption syndrome

ii. Any of the following within the last 6 months:

1. abdominal fistula
2. gastrointestinal perforation
3. bowel obstruction or gastric outlet obstruction
4. intra-abdominal abscess

Note: Complete resolution of an intra-abdominal abscess must be confirmed prior even if the abscess occurred more that 6 months ago.

c. Other disorders associated with a high risk of fistula formation or wound healing complications, including percutaneous endoscopic gastrostomy (PEG) tube placement within the last 3 months.

d. History of chronic pancreatitis.

10\. Unable to swallow tablets.

11\. Evidence within the last 2 years of another malignancy which required systemic treatment.

12\. Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment.

1. Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatment.
2. Prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment.
3. For Combination Dose Finding and Combination Expansion cohorts only: History of hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins. Hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the Lead PI.
4. Radionuclide treatment, including yttrium-90 treatment, within 6 weeks of the first dose of study treatment.
5. Radiation therapy:

a. to the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has ongoing complications or is without complete recovery and healing from prior radiation therapy b. to bone metastases within 14 days of the first dose of study treatment c. to any other site(s) within 28 days of the first dose of study treatment
6. Any other type of investigational agent within 28 days before the first dose of study treatment.
7. Not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia, oxaliplatin-related neuropathy, and other non-clinically significant adverse events.
8. Presence of or known history of brain/ CNS tumor or metastases.
9. KRAS exon 2 (codons 12 or 13) mutation detected in tumor tissue specimen.
10. Concurrent severe and/or uncontrolled medical conditions which may compromise participation in the study, including impaired heart function or clinically significant heart disease.
11. Prothrombin time (PT) or partial thromboplastin time (PTT) test ≥ 1.3 x laboratory upper limit of normal (ULN) within 7 days before the first dose of study treatment.
12. Concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel). Low dose aspirin (≤ 81 mg/day), low-dose warfarin (≤ 1 mg/day), and prophylactic LMWH are permitted.
13. Chronic concomitant treatment of strong CYP3A4 inducers or CYP3A4 inhibitors.
14. Previously experienced any of the following:

1. clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment
2. hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment
3. any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
15. Radiographic evidence of cavitating pulmonary lesion(s).
16. Tumor in contact with, invading or encasing any major blood vessels.
17. Evidence of endotracheal or endobronchial tumor.
18. Uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

1. Cardiovascular disorders including:

i. Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening

ii. Concurrent uncontrolled hypertension defined as sustained BP \> 140 mm Hg systolic, or \> 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment

iii. Any history of congenital long QT syndrome

iv. Any of the following within 6 months before the first dose of study treatment:

1. unstable angina pectoris
2. clinically-significant cardiac arrhythmias
3. stroke (including TIA, or other ischemic event)
4. myocardial infarction
5. thromboembolic event requiring therapeutic anticoagulation

Note: Subjects with a venous filter (e.g., vena cava filter) are not eligible for this study.

b. Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:

i. Any of the following within 28 days before the first dose of study treatment



1. active peptic ulcer disease
2. active inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
3. malabsorption syndrome

ii. Any of the following within 6 months before the first dose of study treatment:

1. abdominal fistula
2. gastrointestinal perforation
3. bowel obstruction or gastric outlet obstruction
4. intra-abdominal abscess

Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more that 6 months before the first dose of study treatment.

c. Other disorders associated with a high risk of fistula formation or wound healing complications, including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy.

d. History of chronic pancreatitis.

e. Other clinically significant disorders such as:

i. active infection requiring IV antibiotic within 28 days before the first dose of study treatment

ii. serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment

iii. history of organ transplant

iv. concurrent uncompensated hypothyroidism or thyroid dysfunction

Note: Patients with newly diagnosed thyroid conditions may participate if stable on a new regimen for at least 7 days before the first dose of study treatment.

v. history of surgery as follows:

1. major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications
2. minor surgery, including dental procedures, within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications

In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery.

19\. History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.

20\. Unable to swallow tablets.

21\. Corrected QT interval calculated by the Fridericia formula (QTcF) \> 500 ms within 28 days before start of treatment. Note: At baseline (i.e. screening), three ECGs to be obtained within 30 minutes but approximately 2 minutes apart (i.e. triplicate). If the average of the three consecutive results for QTcF is ≤ 500 ms, the subject meets eligibility in this regard.

22\. Pregnant or breastfeeding.

23\. For the Combination Dose Finding and Combination Expansion cohorts only: Previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumab.

24\. Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

25\. Evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment.

26\. Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No